Last updated: 7 June 2024 at 4:39pm EST

Jonathan Allan J.D. Net Worth




The estimated Net Worth of Jonathan Allan is at least $259 mil dollars as of 20 May 2024. Mr Allan owns over 8,599 units of Stoke Therapeutics stock worth over $165,044 and over the last 2 years he sold STOK stock worth over $93,922.

Mr D STOK stock SEC Form 4 insiders trading

Mr has made over 4 trades of the Stoke Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 8,599 units of STOK stock worth $60,795 on 20 May 2024.

The largest trade he's ever made was exercising 8,599 units of Stoke Therapeutics stock on 20 May 2024 worth over $60,795. On average, Mr trades about 3,307 units every 48 days since 2023. As of 20 May 2024 he still owns at least 11,197 units of Stoke Therapeutics stock.

You can see the complete history of Mr Allan stock trades at the bottom of the page.





Mr. Jonathan Allan J.D. biography

Jonathan Allan J.D. is the Deputy Gen. Counsel at Stoke Therapeutics.



What's Mr D's mailing address?

Jonathan's mailing address filed with the SEC is C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD, MA, 01730.

Insiders trading at Stoke Therapeutics

Over the last 5 years, insiders at Stoke Therapeutics have traded over $49,612,288 worth of Stoke Therapeutics stock and bought 4,288,550 units worth $94,976,062 . The most active insiders traders include Group, Llc Green Jeremy Red..., Investments, Lpwong Roderic..., eTrust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of $1,639,987. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth $6,000.



What does Stoke Therapeutics do?

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.



Complete history of Mr Allan stock trades at Stoke Therapeutics

Acionista maioritário
Trans.
Transação
Preço total
Jonathan Allan
Conselho Geral e CORP SEC
Exercício de opção $60,795
20 May 2024
Jonathan Allan
Conselho Geral e CORP SEC
Venda $67,663
28 Mar 2024
Jonathan Allan
Conselho Geral e CORP SEC
Exercício de opção $47,765
15 Mar 2024
Jonathan Allan
Conselho Geral e CORP SEC
Venda $26,259
21 Jun 2023


Stoke Therapeutics executives and stock owners

Stoke Therapeutics executives and other stock owners filed with the SEC include: